News
-
4DMT and Astellas Enter into License Agreement to Use 4DMT’s Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets
-
Eli Lilly Announces Acquisition Of Sigilon Therapeutics
-
Insilico Medicine’s Transformer-based Aging Clock Provides Insights Into Aging, Disease, And New Therapeutic Targets
-
Insilico Medicine Announces Potential Best-In-Class Pan-TEAD Inhibitor Candidate ISM6331 Targeting Advanced Solid Tumors
-
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
-
Insilico Medicine Receives IND Approval For Novel AI-designed USP1 Inhibitor For Cancer
-
Freenome Invests $16M To Acquire Fellow Cancer Test Maker Oncimmune